Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Risueno A, See WL, Bluemmert I, de Botton S, et al. Leuk Res 2024;140:107497.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Risueno A, See WL, Bluemmert I, de Botton S, et al. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leuk Res 2024;140:107497.
PMID: 38564986